Investigations on the cytochrome P450 (CYP) isoenzymes involved in the metabolism of the designer drugs N-(1-phenyl cyclohexyl)-2-ethoxyethanamine and N-(1-phenylcyclohexyl)-2-methoxyethanamine

Biochemical Pharmacology

Volumn 77, Issue 3, 2009, Pages 444-450

  Sauer, Christoph ^a   Peters, Frank T ^a   Schwaninger, Andrea E ^a   Meyer, Markus R ^a   Maurer, Hans H ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Cytochrome P450; Designer drugs; HLM; N (1 Phenylcyclohexyl) 2 ethoxyethanamine; N (1 Phenylcyclohexyl) 2 methoxyethanamine

Indexed keywords

4 (4 CHLOROBENZYL)PYRIDINE; CYTOCHROME P450; CYTOCHROME P450 2B6; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DESIGNER DRUG; KETOCONAZOLE; N (1 PHENYLCYCLOHEXYL) 2 METHOXYETHANAMINE; N (1PHENYLCYCLOHEXYL) 2 ETHOXYETHANAMINE; SULFAPHENAZOLE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; DEETHYLATION; DEMETHYLATION; DRUG CLEARANCE; DRUG METABOLISM; INCUBATION TIME; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL;

CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DESIGNER DRUGS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; ISOENZYMES; PHENCYCLIDINE;

EID: 58249130589     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.10.024     Document Type: Article

References (32)

1. Guengerich F.P. Human cytochrome P450 enzymes. In: Ortiz-de-Montellano P.R. (Ed). Cytochrome P450-structure, mechanism, and biochemistry. 3rd ed. (2005), Kluwer Academic/Plenum Publishers, New York 377-530
2. Tucker G.T., Lennard M.S., Ellis S.W., Woods H.F., Cho A.K., Lin L.Y., et al. The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 47 (1994) 1151-1156
3. Wu D., Otton S.V., Inaba T., Kalow W., and Sellers E.M. Interactions of amphetamine analogs with human liver CYP2D6. Biochem Pharmacol 53 (1997) 1605-1612
4. Roesner P., Junge T., Fritschi G., Klein B., Thielert K., and Kozlowski M. Neue synthetische drogen: piperazin- procyclidin- und alpha-aminopropiophenonderivate. Toxichem Krimtech 66 (1999) 81-90
5. Maddox V.H., Godefroi E.F., and Parcell R.F. Synthesis of phencyclidine and other 1-arylcyclohexylamines. J Med Chem 8 (1965) 230-235
6. Rang H.P., Dale M.M., and Ritter J.M. Pharmacology. 4th ed. (1999), Churchill Livingston, London
7. Sauer C., Peters F.T., Staack R.F., Fritschi G., and Maurer H.H. Metabolism and toxicological detection of a new designer drug, N-(1-phenylcyclohexyl)propanamine, in rat urine using gas chromatography-mass spectrometry. J Chromatogr A 1186 (2008) 380-390
8. Sauer C., Peters F.T., Staack R.F., Fritschi G., and Maurer H.H. New designer drug (1-(1-phenylcyclohexyl)-3-ethoxypropylamine (PCEPA): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. J Mass Spectrom 41 (2006) 1014-1029
9. Sauer C., Peters F.T., Staack R.F., Fritschi G., and Maurer H.H. New designer drugs N-(1-phenylcyclohexyl)-2-ethoxyethanamine (PCEEA) and N-(1-phenylcyclohexyl)-2-methoxyethanamine (PCMEA): studies on their metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J Mass Spectrom 43 (2008) 305-316
10. Sauer C., Peters F.T., Staack R.F., Fritschi G., and Maurer HH. Metabolism and toxicological detection of the designer drug N-(1-phenylcyclohexyl)-3-methoxypropanamine (PCMPA) in rat urine using gas chromatography-mass spectrometry. Forensic Sci Int 181 (2009) 47-51
11. Takeda H., Gazzara R.A., and Howard S.G. Phenylcyclohexylamine: effect of a metabolite of phencyclidine on the efflux of dopamine in the rat. Neuropharmacology 25 (1986) 1341-1345
12. Peters F.T., Schwaninger A.E., Dragan C.A., Sauer C., Fritschi G., Bureik M., et al. Isolation and purification of the designer drug metabolite O-deethyl-(1-phenylcyclohexyl)-3-ethoxypropanamine (O-deethyl-PCEPA)-biotechnologically synthesized using fission yeast expressing CYP2D6. In: Pragst F., and Aderjan R. (Eds). Current Contributions to Forensic and Clinical Toxicology, Proceedings of the XVth GTFCh Symposium. Mosbach, Germany, April 18-21, 2007. Bad Vilbel (Germany): GTFCH (2008) 204-210
13. Sauer C., Peters F.T., Schwaninger A.E., Meyer M.R., and Maurer H.H. Identification of cytochrome P450 enzymes involved in the metabolism of the designer drugs N-(1-phenylcyclohexyl)-3-ethoxypropanamine (PCEPA) and N-(1-phenylcyclohexyl)-3-methoxypropanamine (PCMPA). Chem Res Toxicol 21 (2008) 1949-1955
14. Clarke S.E. In vitro assessment of human cytochrome P450. Xenobiotica 28 (1998) 1167-1202
15. Crespi C.L., and Miller V.P. The use of heterologously expressed drug metabolizing enzymes-state of the art and prospects for the future. Pharmacol Ther 84 (1999) 121-131
16. Venkatakrishnan K., von Moltke L.L., Court M.H., Harmatz J.S., Crespi C.L., and Greenblatt D.J. Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Dispos 28 (2000) 1493-1504
17. Crespi C.L. Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. In: Testa B., and Meyer U.A. (Eds). Advances in Drug Research. 26th ed. (1995), Academic Press, London 179-235
18. Crespi C.L., and Penman B.W. Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions. Adv Pharmacol 43 (1997) 171-188
19. Sauer C., Peters F.T., Staack R.F., Fritschi G., and Maurer H.H. Comparative studies on the metabolism and the detection of phencyclidine-derived designer drugs in rat urine using GC-MS techniques. In: Pragst F., and Aderjan R. (Eds). Current Contributions to Forensic and Clinical Toxicology, Proceedings of the XVth GTFCh Symposium. Mosbach, Germany, April 18-21, 2007. Bad Vilbel (Germany): GTFCh (2008) 204-210
20. Korhonen L.E., Turpeinen M., Rahnasto M., Wittekindt C., Poso A., Pelkonen O., et al. New potent and selective cytochrome P450 2B6 (CYP2B6) inhibitors based on three-dimensional quantitative structure-activity relationship (3D-QSAR) analysis. Br J Pharmacol 150 (2007) 932-942
21. Newton D.J., Wang R.W., and Lu A.Y. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23 (1995) 154-158
22. Bourrie M., Meunier V., Berger Y., and Fabre G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277 (1996) 321-332
23. Wienkers L.C., Wurden C.J., Storch E., Kunze K.L., Rettie A.E., and Trager W.F. Formation of (R)-8-hydroxywarfarin in human liver microsomes: a new metabolic marker for the (S)-mephenytoin hydroxylase. P4502C19. Drug Metab Dispos 24 (1996) 610-614
24. Venkatakrishnan K., von Moltke L.L., and Greenblatt D.J. Effects of the antifungal agents on oxidative drug metabolism. Clinical relevance. Clin Pharmacokinet 38 (2000) 111-180
25. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry: Drug interaction studies-study design, data analysis, and implications for dosing and labeling [draft] 2006.
26. Huang S.M., Temple R., Throckmorton D.C., and Lesko L.J. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 81 (2007) 298-304
27. Brown H.S., Chadwick A., and Houston J.B. Use of isolated hepatocyte preparations for cytochrome P450 inhibition studies: comparison with microsomes for Ki determination. Drug Metab Dispos 35 (2007) 2119-2126
28. Bailey D.N., and Guba J.J. Gas-chromatographic analysis for phencyclidine in plasma, with use of a nitrogen detector. Clin Chem 26 (1980) 437-440
29. Lerner S.E., and Burns R.S. Legal issues associated with PCP abuse-the role of the forensic expert. NIDA Res Monogr 64 (1986) 229-236
30. Turpeinen M., Raunio H., and Pelkonen O. The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico. Curr Drug Metab 7 (2006) 705-714
31. Rae J.M., Soukhova N.V., Flockhart D.A., and Desta Z. Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. Drug Metab Dispos 30 (2002) 525-530
32. Hesse L.M., Venkatakrishnan K., Court M.H., von Moltke L.L., Duan S.X., Shader R.I., et al. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28 (2000) 1176-1183